Soft Tissue Sarcoma in Dogs: Margins, Recurrence, and Why a Lump Removal Isn't Enough
A decision-grade guide to canine soft tissue sarcoma: how tumor grade and surgical margins dictate recurrence, when to perform scar revision vs radiation, and metronomic chemotherapy.
Soft tissue sarcomas (STS) are a diverse family of malignant tumors arising from the body’s connective, support, or surrounding tissues. While they represent approximately 15% of all subcutaneous and cutaneous tumors in dogs, they present a distinct clinical challenge. Rather than acting as discrete, encapsulated masses, soft tissue sarcomas are notorious for their local invasiveness. They grow by expanding outward and compressing surrounding cancer cells into a "pseudocapsule." To a surgeon during a standard "lump removal," this pseudocapsule can make the tumor appear well-demarcated and easily shellable. However, this capsule is microscopically infiltrated by neoplastic finger-like projections.
A simple marginal excision—what is commonly referred to as a "lumpectomy" or a close-margin lump removal—is highly likely to leave microscopically incomplete margins, leading to local recurrence rates as high as 17% to 41% within three years, and up to 75% in some clinical series.
For veterinary general practitioners and proactive pet owners, managing a canine soft tissue sarcoma requires shifting the therapeutic goal from simple removal to achieving definitive surgical margins or coordinating adjuvant therapies. The histologic grade of the tumor and the cleanliness of the surgical margins are the primary drivers of the dog’s long-term prognosis.
Quick Answer: The Grade-and-Margin Rule
A canine soft tissue sarcoma’s behavior and prognosis are determined by its histologic grade and surgical margin status, rather than its specific anatomical subtype (such as fibrosarcoma or peripheral nerve sheath tumor).
- Surgical Goal: The standard curative-intent surgery requires wide excision with lateral margins of at least 3 cm of normal tissue and a depth of at least one clean fascial plane. Simple marginal lump removals frequently leave tumor cells behind.
- If Margins Are Incomplete: For an incompletely excised tumor, the next step should not be passive observation. The recommended paths are either a prompt scar-revision surgery (re-operating to excise the previous surgical scar and obtain clean margins) or definitive radiation therapy.
- Prognosis:
- Grade I (Low-Grade): Very low metastatic rate (<10%). If completely excised, the local recurrence rate is under 7%, and median survival is measured in years (often normal life expectancy).
- Grade II (Intermediate): Moderate metastatic risk (10–20%). Local recurrence is manageable with clean margins; survival is typically multi-year.
- Grade III (High-Grade): High metastatic risk (40–50%), primarily to the lungs. Median survival is shorter (often 1 to 2 years), requiring staging and consideration of systemic chemotherapy.
What Is a Soft Tissue Sarcoma, and Why Does Grade Matter More Than Subtype?
Soft tissue sarcomas originate from mesenchymal cells. Because connective tissue exists throughout the body, these tumors can develop almost anywhere, though they are most frequently identified in the skin and subcutaneous tissues of the limbs, trunk, and head.
Historically, pathologists categorized these tumors strictly by their tissue of origin. This resulted in a long list of distinct diagnoses, including:
- Fibrosarcoma: Arising from fibrous connective tissue.
- Peripheral Nerve Sheath Tumor (PNST): Also known as schwannoma or neurofibrosarcoma, arising from the sheath surrounding nerves.
- Myxosarcoma: Characterized by an abundant mucinous extracellular matrix.
- Liposarcoma: Arising from fat cells (distinct from benign lipomas).
- Perivascular Wall Tumor (PWT): Formerly grouped under hemangiopericytomas, arising from the cells surrounding blood vessels.
- Pleomorphic Sarcoma / Undifferentiated Sarcoma: Lacking distinct cellular differentiation.
While these terms are useful for pathology reporting, clinical studies—including the 2026 Frontiers in Veterinary Science Oncology Consensus Report—confirm that these subtypes behave similarly and are treated under the same clinical protocol. The specific histological subtype does not dictate the patient's prognosis. Instead, the tumor's clinical behavior, metastatic potential, and local recurrence risk are driven by the histologic grade and the surgical margins.
The Histologic Grading System
Veterinary pathologists grade canine soft tissue sarcomas on a scale of I to III (or low, intermediate, and high grade) using a standardized system originally developed by Bostock and modified by Dennis et al. (2011). The grade is determined by evaluating three distinct features under the microscope:
- Cellular Differentiation: How closely the tumor cells resemble normal, mature mesenchymal cells.
- Score 1: Highly differentiated (resembles normal tissue).
- Score 2: Moderately differentiated (cellular origin is still identifiable).
- Score 3: Poorly differentiated or undifferentiated (highly abnormal, giant multinucleated cells).
- Mitotic Count: The number of mitotic figures (cells actively dividing) observed in 10 high-power fields (HPF).
- Score 1: 0 to 9 mitoses per 10 HPF.
- Score 2: 10 to 19 mitoses per 10 HPF.
- Score 3: 20 or more mitoses per 10 HPF.
- Tumor Necrosis: The percentage of dead tumor tissue within the sample, which indicates rapid, uncontrolled growth outstripping the blood supply.
- Score 0: No necrosis.
- Score 1: Less than 50% necrosis.
- Score 2: 50% or more necrosis.
The scores from these three categories are added together to determine the overall histologic grade:
- Grade I (Total Score 2–3): Low metastatic risk, slow local growth.
- Grade II (Total Score 4–5): Intermediate metastatic risk, moderate local invasiveness.
- Grade III (Total Score 6–8): High metastatic risk, highly aggressive local invasion.
| Histologic Grade | Mitotic Count (per 10 HPF) | Metastatic Rate | Median Survival Time (Surgery + RT) | Key Treatment Focus |
|---|---|---|---|---|
| Grade I (Low) | 0 – 9 | < 10% | 1,445 Days (~4 years) | Local control (Wide surgical excision) |
| Grade II (Intermediate) | 10 – 19 | 10% – 20% | 1,201 Days (~3.3 years) | Local control; active staging monitor |
| Grade III (High) | ≥ 20 | 40% – 50% | 767 Days (~2.1 years) | Surgery + Staging + Chemotherapy |
Why a Marginal "Lump Removal" Is Not Enough
The most common pitfall in veterinary oncology is the accidental marginal excision of a soft tissue sarcoma. Because these tumors are slow-growing and painless in their early stages, they are frequently mistaken for benign lipomas, sebaceous cysts, or skin tags.
Under the skin, a soft tissue sarcoma does not possess a true, fibrous capsule that isolates it from the body. Instead, as the tumor expands, it compresses the surrounding healthy tissue. This compressed zone of healthy tissue, inflammatory cells, and outward-pushing tumor cells is called a pseudocapsule.
When a veterinarian performs a simple excisional biopsy—peeling the lump out along the natural plane of this "capsule"—they are performing a marginal excision. The surgeon’s hands feel like the mass came out cleanly, but microscopically, the pseudocapsule is filled with active tumor cells. By cutting along the capsule, the surgeon leaves behind microscopic disease in the surrounding tissue bed.
The Data on Recurrence
Leaving microscopic disease behind dramatically increases the likelihood that the tumor will grow back.
- An Oregon State University meta-analysis (Milovancev et al., published in Veterinary and Comparative Oncology) evaluated 10 studies covering 278 dogs. The analysis found that achieving microscopically complete surgical margins reduced the risk of local recurrence by 60%.
- The recurrence rate for completely excised soft tissue sarcomas is under 10% (typically around 7%).
- If the excision is incomplete, the local recurrence rate rises to 33% to 41%, and can exceed 70% for high-grade tumors.
- A landmark retrospective study (PMC9754140) tracking local recurrence hazard ratios found that narrow margins (<3 mm) carried a 3.2× hazard increase of recurrence compared to clean margins, while incomplete margins carried a 6.2× hazard increase.
This behavior is similar to feline injection-site sarcomas, which also invade tissue locally. However, while feline injection-site sarcomas require highly aggressive 5 cm lateral margins due to their inflammatory nature, canine spontaneous soft tissue sarcomas are typically managed with 3 cm margins.
Clean, Narrow, or Incomplete Margins: What Do the Results Mean?
Once a tumor is removed and submitted for histopathology, the pathologist evaluates the tissue margins. Margins are reported in three categories:
VISUALIZING SURGICAL MARGINS
[ INCOMPLETE ] [ NARROW ] [ COMPLETE ]
|───────────────────| |───────────────────| |───────────────────|
| * * * * * * | | * * * * | | * * * |
| * Tumor * * *| [Ink]| * Tumor * | [Ink]| * Tumor | [Ink]
| * * * * * *─┼──────| * * * | | * |
| | | < 3 mm | | 3 mm to 3 cm |
(Tumor cells at ink) (Microscopic gap) (Wide safety zone)
1. Complete (Clean) Margins
The pathologist observes a continuous zone of healthy, non-cancerous tissue between the outer edge of the tumor and the surgical ink. In veterinary oncology, a margin is generally considered "complete" if there is a barrier of at least 3 mm of healthy tissue, or if a dense, intact fascial plane exists beneath the tumor.
- Prognosis: Excellent for Grade I and II tumors. The risk of local recurrence is very low (7%).
- Action Plan: Passive monitoring. The owner or GP should palpate the surgical site monthly.
2. Incomplete Margins
Tumor cells are observed directly at the surgical ink, meaning the surgeon cut directly through the cancer tissue. Microscopic disease remains in the patient.
- Prognosis: High risk of local recurrence (33% to 41.2% within three years).
- Action Plan: Immediate intervention is indicated. Passive monitoring is discouraged, as recurring tumors are often more aggressive and harder to excise.
3. Narrow Margins
Tumor cells are not at the ink, but the distance between the tumor and the ink is less than 3 mm, and no fascial plane is present. This is common when removing masses from the limbs, where there is little spare skin or muscle to harvest.
- Prognosis: Moderate risk of local recurrence (22.5% within three years).
- Action Plan: The choice between active monitoring and immediate intervention depends on the tumor's histologic grade and mitotic index. For a Grade I tumor with a mitotic index of 0, close observation may be reasonable; for a Grade II or III tumor, intervention is indicated.
Next Steps for Incomplete or Narrow Margins
If the pathology report indicates narrow or incomplete margins, three management pathways should be considered:
Pathway A: Scar-Revision Surgery (The Preferred Approach)
If the tumor was located on the trunk, lateral thorax, or abdomen where skin is redundant, a second surgery is the most effective next step. The surgeon re-opens the site to excise the previous surgical scar, the skin surrounding the incision, and the entire underlying tissue bed down to the next fascial plane.
The clinical objective of scar revision is to treat the previous incision as the new "tumor center" and apply the same wide-margin principles (3 cm lateral margins from the scar edges and a deep fascial plane). This removes any micro-extensions of the sarcoma that were missed during the first attempt.
- Efficacy: A retrospective study published in the peer-reviewed literature (indexed as PMC9754140) evaluated 33 dogs that underwent scar-revision surgery for incompletely or narrowly excised canine soft tissue sarcomas. The study reported a remarkably low 3.0% (1/33) local recurrence rate following scar-revision surgery, confirming that a secondary wide excision is highly curative when anatomical space allows.
- Feasibility: This approach is highly effective if there is enough local tissue to close the resulting wound without excessive tension. It is more difficult to execute on the distal limbs, head, or neck, where primary closure of a wide wound is restricted and complex skin flaps, grafts, or even limb amputation may be required.
- Surgical Note: To prevent cross-contamination or tumor cell seeding, surgeons must use clean instruments and change gloves after dissecting the scar tissue, before preparing the wound bed for closure.
Pathway B: Postoperative Radiation Therapy (RT)
If the tumor was located on a limb or the head, re-excision may not be possible without causing severe functional impairment or requiring limb amputation. In these cases, definitive-intent radiation therapy is the standard recommendation.
Radiation targets the surgical bed with high-energy beams to destroy remaining microscopic tumor cells.
- Protocol: Typically involves 15 to 20 daily fractions administered Monday through Friday over three to four weeks.
- Efficacy: A 2025 JAVMA study evaluated 272 dogs treated with surgery followed by postoperative definitive radiotherapy. The median survival times were:
- Grade I: 1,445 days
- Grade II: 1,201 days
- Grade III: 767 days
- This study represents the current best clinical evidence for intermediate-to-long-term control using combination therapy.
Pathway C: Active Surveillance (Watchful Waiting)
In some cases, active surveillance may be chosen due to financial constraints, patient comorbidities, or advanced age.
- When to consider: Only for Grade I tumors with low mitotic indexes (<5 mitoses/10 HPF) and narrow (rather than incomplete) margins.
- Monitoring Protocol: The incision site must be palpated every 2 to 4 weeks. If a recurrence is detected early, a second surgery should be scheduled immediately.
Metastasis, Staging, and Systemic Therapy
While soft tissue sarcomas are highly invasive locally, their risk of spreading to distant organs (metastasis) is relatively low for Grade I and II tumors. Spread occurs hematogenously (through the bloodstream), primarily to the lungs, and occasionally to regional lymph nodes.
The Staging Protocol
Staging is the diagnostic process of checking the rest of the body for cancer before planning aggressive local therapies. Staging should be performed for all Grade II and III soft tissue sarcomas, and prior to any definitive surgery or radiation therapy. The protocol includes:
- Three-View Thoracic Radiographics: Checking for pulmonary nodules (metastasis).
- Fine-Needle Aspiration (FNA) of Regional Lymph Nodes: Evaluating the local lymph nodes for metastatic spread.
- Abdominal Ultrasound: Checking for internal organ involvement (primarily for high-grade or atypical presentations).
Systemic Chemotherapy
Traditional maximum-tolerated-dose (MTD) chemotherapy (using drugs like doxorubicin) is rarely indicated for Grade I or II soft tissue sarcomas, as these tumors are relatively chemoresistant. However, chemotherapy should be considered for Grade III tumors, which carry a 40% to 50% risk of metastasis.
For incomplete margins where further surgery or radiation is not feasible, metronomic chemotherapy is an alternative. Rather than using high doses of drugs to kill tumor cells directly, metronomic chemotherapy uses low, daily, oral doses of drugs to inhibit angiogenesis (the growth of new blood vessels that feed microscopic tumors).
- Standard Protocol: Daily oral cyclophosphamide combined with a non-steroidal anti-inflammatory drug (NSAID) such as piroxicam.
- Efficacy: A study by Elmslie et al. (published in the Journal of Veterinary Internal Medicine) demonstrated that this metronomic protocol effectively delayed the local recurrence of incompletely resected soft tissue sarcomas in dogs compared to untreated historical controls.
GP vs. Specialist: When to Refer Upfront
Veterinary general practitioners routinely perform minor lump removals. However, because the first surgery provides the best opportunity to achieve clean margins, identifying high-risk masses before operating is critical.
PRE-OPERATIVE REFERRAL DECISION MATRIX
[ EVALUATE LUMP ] ──> Is it > 3 cm, fixed to tissue, or on an extremity?
│
┌───────────────┴───────────────┐
YES NO
│ │
[ STAGE & REFER ] [ GP CAN PERFORM ]
• Perform FNA & Staging • GP performs excision
• Refer to Surgeon/Oncologist • Aim for wide margins
• Plan wide margins upfront • Submit entire mass for biopsy
Recommending Upfront Referral
A patient should be referred to a board-certified veterinary surgeon or oncologist prior to the first surgery if the mass exhibits any of the following traits:
- Size: The mass is larger than 3 cm in diameter.
- Fixity: The mass is firmly attached to underlying muscle, bone, or fascia (indicating it has already invaded deep tissue planes).
- Location: The mass is located on a limb, the head, or the neck, where achieving 3 cm lateral margins requires reconstructive surgery (such as skin grafts or rotary flaps) or amputation.
- Recurrence: The mass is a recurrence of a previously removed tumor.
Referral allows for advanced planning, which may include pre-operative CT scans to map the tumor's deep extensions and ensure the first surgical attempt is curative.
The Cost of Care: Treatment Cost Map
Managing a canine soft tissue sarcoma involves several potential cost layers. The table below outlines typical cost ranges in veterinary medicine as of 2026.
| Care Phase | Diagnostic or Treatment Step | Cost Range | Key Value Delivered |
|---|---|---|---|
| Diagnostics & Staging | Fine-needle aspiration + cytology | $150 – $350 | Confirms mesenchymal tumor |
| Full staging (Chest rads, lab work, FNA) | $600 – $1,200 | Rules out metastasis before surgery | |
| Surgical Excision | Standard GP wide surgical excision | $1,500 – $3,500 | Primary treatment for mobile trunk masses |
| Specialist surgical excision (ACVS) | $3,000 – $6,000 | Recommended for limbs, head, or large masses | |
| Adjuvant Options | Scar-revision surgery (GP or Specialist) | $2,000 – $4,500 | Secures margins after an incomplete cut |
| Definitive Radiation Course (15–20 daily sessions) | $6,000 – $10,000 | Prevents recurrence when margins are incomplete | |
| Metronomic Chemotherapy (Cyclophosphamide/Piroxicam) | $150 – $300 / mo | Delays recurrence for incomplete margins |
Owners facing these treatment costs should consult their insurance providers. For a detailed breakdown of oncology coverage, see our guide on does pet insurance cover prescriptions and our general dog cancer treatment cost map.
Frequently Asked Questions
How long do dogs live with a soft tissue sarcoma?
Prognosis is highly dependent on the tumor's histologic grade and whether complete surgical removal was achieved. Dogs with Grade I (low-grade) or Grade II (intermediate-grade) tumors that are completely excised with clean margins frequently live for 3 to 5+ years, often dying of unrelated age-related causes. For Grade III (high-grade) tumors, even with surgery and radiation, the median survival time is shorter, typically ranging from 1 to 2 years, due to the high risk of lung metastasis.
If my dog's lump was removed but the margins were incomplete, does it always come back?
No, it does not always recur, but the risk is high (33% to 41.2% within three years). Recurrence is driven by the histologic grade. A Grade I tumor with incomplete margins may take years to recur or may never cause clinical issues, whereas a Grade III tumor with incomplete margins is highly likely to recur rapidly and aggressively.
Does soft tissue sarcoma in dogs spread, and to where?
Yes, but the likelihood depends on the grade. Grade I tumors have a metastatic rate of less than 10%, Grade II tumors range from 10% to 20%, and Grade III tumors carry a 40% to 50% risk of spread. When metastasis occurs, it travels hematogenously (through the blood) to the lungs, or less commonly to the local lymph nodes. It does not typically spread to other organs first.
Sources
- Frontiers in Veterinary Science (2026): Canine cutaneous and subcutaneous soft tissue sarcoma in dogs: a consensus report. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2026.1750148/full
- Journal of the American Veterinary Medical Association (2025): Surgery and postoperative definitive radiotherapy for canine soft tissue sarcoma: 272 dogs (2010–2020). https://avmajournals.avma.org/view/journals/javma/263/3/javma.24.06.0363.xml
- PubMed / Case Series (PMC9754140): Scar revision for incompletely or narrowly excised soft tissue sarcomas in dogs. https://pmc.ncbi.nlm.nih.gov/articles/PMC9754140
- Journal of Small Animal Practice (2016): Soft tissue sarcoma in the dog: Part 1 and Part 2. https://onlinelibrary.wiley.com/doi/10.1111/jsap.12556
- MDPI Veterinary Sciences (2024): A Review on Canine and Human Soft Tissue Sarcomas: prognostic factors and treatment. https://www.mdpi.com/2306-7381/11/8/362
- Oregon State University / Veterinary and Comparative Oncology (Milovancev et al. meta-analysis): Complete tumor removal reduces recurrence risk in dogs. https://news.oregonstate.edu/news/complete-removal-tumor-reduces-risk-recurrence-cancer-dogs-analysis-shows
- Veterinary Pathology (2011): Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs (Dennis MM et al.). https://pubmed.ncbi.nlm.nih.gov/?term=Dennis+soft+tissue+sarcoma+canine+2011
- Cornell University Riney Canine Health Center: Soft Tissue Sarcomas in Dogs. https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/soft-tissue-sarcomas-dogs
- Journal of Veterinary Internal Medicine (Elmslie et al. 2008): Metronomic cyclophosphamide and piroxicam delay recurrence of canine soft tissue sarcomas. https://www.vin.com/apputil/content/defaultadv1.aspx?pId=22915&catId=124650&id=8896608
